2021

1. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

   The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154